Becker Capital Management Inc. lowered its stake in Eli Lilly and Co. (NYSE:LLY) by 2.8% during the second quarter, Holdings Channel reports. The firm owned 10,932 shares of the company’s stock after selling 318 shares during the period. Becker Capital Management Inc.’s holdings in Eli Lilly and were worth $861,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock worth $159,402,000 after buying an additional 1,880,800 shares during the period. Beutel Goodman & Co Ltd. purchased a new stake in shares of Eli Lilly and during the second quarter worth about $104,345,000. Bank of Montreal Can purchased a new stake in shares of Eli Lilly and during the second quarter worth about $86,545,000. Svenska Handelsbanken AB publ purchased a new stake in shares of Eli Lilly and during the second quarter worth about $57,606,000. Finally, Sector Gamma AS boosted its stake in shares of Eli Lilly and by 89.8% in the first quarter. Sector Gamma AS now owns 771,390 shares of the company’s stock worth $55,548,000 after buying an additional 365,000 shares during the period. Institutional investors own 74.99% of the company’s stock.
Eli Lilly and Co. (NYSE:LLY) traded down 2.14% during midday trading on Friday, hitting $74.53. 5,651,541 shares of the stock traded hands. The company has a 50-day moving average of $79.52 and a 200-day moving average of $78.09. Eli Lilly and Co. has a 12 month low of $67.88 and a 12 month high of $88.16. The stock has a market cap of $79.06 billion, a PE ratio of 32.42 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by $0.08. Eli Lilly and had a net margin of 11.73% and a return on equity of 24.06%. The company earned $5.19 billion during the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter last year, the firm earned $0.89 EPS. Eli Lilly and’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Co. will post $3.56 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 2.74%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s dividend payout ratio is presently 88.70%.
A number of brokerages recently issued reports on LLY. Jefferies Group reissued a “buy” rating and issued a $100.00 target price (down from $105.00) on shares of Eli Lilly and in a research report on Friday. Argus upped their target price on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 target price for the company in a research report on Friday, July 29th. BMO Capital Markets reissued a “buy” rating and issued a $94.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 27th. Finally, Leerink Swann reissued an “outperform” rating and issued a $105.00 target price on shares of Eli Lilly and in a research report on Saturday, August 13th. Two analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Buy” and an average target price of $96.74.
In other Eli Lilly and news, Director Jackson P. Tai purchased 2,560 shares of the stock in a transaction on Friday, August 12th. The stock was acquired at an average price of $80.42 per share, with a total value of $205,875.20. Following the completion of the acquisition, the director now owns 42,110 shares in the company, valued at $3,386,486.20. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Jackson P. Tai purchased 5,773 shares of the stock in a transaction on Monday, August 15th. The stock was acquired at an average cost of $80.43 per share, with a total value of $464,322.39. Following the acquisition, the director now owns 42,306 shares of the company’s stock, valued at approximately $3,402,671.58. The disclosure for this purchase can be found here. 0.20% of the stock is owned by company insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.